Biotech Values

[DewDiligence]

Question for BI, et al, re Protonix case:

If WYE were to launch an authorized generic, how would it affect the assessment of damages in the event WYE eventually prevails in the patent trial? Would an AG launch preclude collecting treble damages or lessen the likelihood of such to a significant degree? T.i.a. Dew